Platelet-Rich Plasma Therapy: Impact on Patient Recovery

Platelet-Rich Plasma Therapy: Dosing and Clinical Use

Abstract

As a clinician deeply invested in integrative and regenerative medicine, I am continually fascinated by the body’s innate capacity for healing. Platelet-Rich Plasma (PRP) therapy stands at the forefront of this field, harnessing and concentrating the body’s own growth factors to accelerate tissue repair and reduce inflammation. In this educational overview, I will guide you through the latest, evidence-based findings from leading researchers on PRP. We will dive into the fundamental biology of platelets, explore the critical concept of therapeutic dosing, and examine how different PRP formulations can influence clinical outcomes, particularly in osteoarthritis and soft tissue injuries. I will also share my clinical observations on how integrating chiropractic care with these regenerative strategies creates a synergistic effect that optimizes patient recovery and functional improvement. This journey will illuminate why not all PRP is created equal and how a precise, evidence-based approach is paramount for success.

The Foundation of PRP: Understanding the Platelet

To truly grasp the power of PRP, we must first revisit a fundamental component of our blood: the platelet. For many, this might be a distant memory from biology class, but for those of us in regenerative medicine, platelets are the stars of the show.

These are not complete cells but rather small, anucleated (lacking a nucleus) cell fragments derived from megakaryocytes in the bone marrow. Despite their simple structure, they are treasure troves packed with a potent arsenal of proteins, including hundreds of growth factors and cytokines. These are the signaling molecules that act as commanders in the body’s healing process, orchestrating tissue repair and regeneration, and modulating inflammation.

• Platelet Lifespan: Platelets have a relatively short half-life of about seven to ten days. This is an important clinical consideration. For example, when we advise patients to discontinue non-steroidal anti-inflammatory drugs (NSAIDs) before a PRP procedure, it’s to ensure the platelets we harvest are fully functional and not inhibited, as NSAIDs can interfere with their activity.
• Normal Concentration: In a typical blood sample, the platelet count ranges from 150,000 to 400,000 per microliter.
• PRP Defined: The goal of PRP therapy is to create a concentrate of these platelets, far exceeding this baseline value. The FDA’s definition of PRP is simply a concentration of platelets above this normal baseline. The essence of the therapy is to collect a patient’s own blood, process it to concentrate these powerful healing cells, and then precisely deliver them to an area of injury or degeneration to initiate a robust healing cascade.

Unpacking the Variability in PRP Formulations

A critical point I emphasize with my patients and colleagues is that “PRP” is not a single, standardized product. There is significant variability among the commercially available systems used to prepare it. This variability can dramatically impact the final biologic product and, consequently, the clinical outcome.

A foundational study from Australia by James Fitzpatrick and his team highlighted this perfectly. They analyzed five different commercial PRP systems and discovered vast differences in two key areas:

1. Platelet Concentration: The final platelet count varied significantly across systems.
2. White Blood Cell (Leukocyte) Count: The systems also produced different concentrations of white blood cells (WBCs), which can influence the post-injection inflammatory response.

Dr. Gerben van Buul’s research provides an even more striking visual. He took blood from a single patient and processed it using four different PRP systems. The resulting PRP products were literally different “colors of the rainbow,” each with a unique cellular composition. This illustrates that the specific system used to create the PRP directly dictates the cellular makeup of the final injection. From my clinical experience at the Health Coach Clinic, I have seen firsthand that understanding and selecting the right system for the specific pathology we treat is crucial to achieving predictable, positive results.

How PRP Is Made: A Step-by-Step Clinical Process

So, how do we get from a simple blood draw to this powerful regenerative injection? The process is a sophisticated application of centrifugation.

1. Blood Draw: We begin by drawing a sample of the patient’s own blood. The volume of the draw is a key variable. A smaller draw will yield fewer total platelets, while a larger draw (e.g., from a 120cc kit) provides a higher starting number, allowing for a more potent final dose. This is a closed, sterile system to ensure safety.
2. First Centrifugation (Spin): The blood is placed in a centrifuge, a machine that spins rapidly. This initial “hard spin” uses centrifugal force to separate the blood components by density. The heavier red blood cells sink to the bottom, the clear, protein-rich plasma rises to the top, and a thin, crucial layer forms in the middle, called the buffy coat. This buffy coat is rich in platelets and white blood cells.
3. Isolation and Concentration: The next step is to carefully isolate this platelet-rich layer. Different systems accomplish this in different ways. In some systems, we then perform a second, gentler spin to further concentrate the platelets while removing unwanted components. The precision here is paramount. For example, in one advanced system, we know that 85% of the platelets are concentrated within a tiny 2-millimeter layer. By skillfully extracting just this layer, we can achieve an extremely high concentration of platelets in a very small volume of plasma—a truly potent product.

Understanding the nuances of the specific system you use is not just technical; it’s essential for maximizing the therapeutic potential of the treatment for each individual patient.

The Critical Concept of Dosing in PRP Therapy

I often explain to my patients that while we don’t regulate PRP like a pharmaceutical drug, we must think of it as a biologic drug. Just like any medication, there is a dose-response relationship. A sub-therapeutic dose will not produce the desired effect, while an excessive dose could potentially be counterproductive. The question then becomes: What is the correct clinical dose of PRP?

The answer is complex and likely varies by the specific tissue being treated (e.g., tendon vs. joint cartilage) and even patient-specific factors like age. However, a growing body of evidence is providing us with clear guidance.

Dosing for Soft Tissue and Tendon Injuries

Early PRP studies often failed to report the specific dose injected, making it difficult to compare results. Thankfully, modern research is correcting this.

• The Dose Threshold: Pioneering work from Dr. Peter Everts’ group provided a crucial insight. They analyzed numerous studies on PRP for soft-tissue applications and plotted them by platelet dose administered. A clear pattern emerged: studies using a dose below 3.5 billion platelets were overwhelmingly negative, showing little to no benefit. In contrast, studies using a dose above 3.5 billion platelets were predominantly positive. This suggests a therapeutic threshold for stimulating effective healing in soft tissues.
• The Biphasic Effect: Research on tendon cells (tenocytes) reveals an even more nuanced dose-response curve. As platelet concentration increases, so does the proliferation of tendon cells—up to a certain point. If the concentration becomes too high, it can actually have an inhibitory effect, reducing cell proliferation. This “bell-shaped curve” demonstrates that more is not always better.
• High-Dose vs. Low-Dose: A large meta-analysis from Dr. Scott Rodeo’s group at HSS further reinforces this. They reviewed studies involving nearly 800 patients and separated them into “low-dose” and “high-dose” PRP groups. The results clearly showed that the high-dose PRP treatments yielded significantly better clinical outcomes.

My clinical takeaway is this: if your system produces only 1.5 billion platelets for a rotator cuff tear, you are likely administering a subtherapeutic dose. To consistently see positive results in soft tissue injuries, we need to aim for a dose in that 3.5 to 5 billion platelet range, or potentially higher.

Dosing for Knee Osteoarthritis (OA)

The knee is perhaps the area where we have the most robust data on PRP dosing.

• The RESTORE Trial: This landmark trial, published in JAMA, initially concluded that PRP was ineffective for knee OA. However, a deep dive into their methodology is revealing. They used a “low-dose” PRP system, injecting only 1.6 billion platelets. Based on what we now know about the dose-response curve, this was a sub-therapeutic dose, virtually guaranteeing a negative result. While the study was beautifully executed, its primary lesson was in helping us define the lower end of the effective dose range.
• The Vangsness Study (High-Dose Success): In stark contrast, a widely cited study by Vangsness et al. used a much higher dose of 10 billion platelets. Patients in this study experienced significant improvements in pain and function. More excitingly, MRI imaging suggested a disease-modifying effect, with evidence that PRP slowed the structural progression of cartilage degradation compared with a control group.
• Multiple Injections: Another study investigated a three-injection protocol, each containing 5 billion platelets (for a total of 15 billion). This protocol also demonstrated significant benefits in pain and function, as well as potential disease-modifying effects.

The emerging consensus for knee OA suggests that an effective single-injection dose is likely in the 5-10 billion platelet range. This is a target I aim for in my practice, tailoring the specific dose to the patient’s age and the severity of their condition. We know that older patients may have less responsive cells, often requiring a higher starting blood volume to achieve the same therapeutic platelet dose.

The Role of Other Cells: Leukocyte-Rich vs. Leukocyte-Poor PRP

Platelets are not the only cells in the PRP formulation. We must also consider the presence of white blood cells (leukocytes), particularly neutrophils and monocytes. This leads to the distinction between Leukocyte-Rich (LR-PRP) and Leukocyte-Poor (LP-PRP).

• Neutrophils: These cells are highly pro-inflammatory. Including a high concentration of neutrophils in the PRP injectate can lead to a more significant post-injection inflammatory response—more pain and swelling in the initial days. For some chronic, non-healing conditions, this acute inflammatory signal can be beneficial, effectively “restarting” the healing process. However, in an already inflamed joint or for certain tissues, this heightened inflammation may be undesirable.
• Monocytes: These are precursors to macrophages, which are critical for cleaning up cellular debris and modulating the later stages of healing. Their presence is generally considered beneficial.

The debate between LR-PRP and LP-PRP is ongoing. Some European data suggest that, for knee OA, there may be no significant long-term clinical difference between the two. However, the initial patient experience is often better with LP-PRP due to the reduced post-injection flare. In my practice, the choice between LR-PRP and LP-PRP is a clinical decision based on the specific condition, the level of existing inflammation, and the therapeutic goal.

The Chiropractic and Integrative Approach: Maximizing PRP Outcomes

PRP therapy is a powerful tool, but it is not a magic bullet. To achieve the best possible outcomes, it must be part of a comprehensive, integrative treatment plan. This is where the synergy of regenerative medicine and chiropractic care becomes so vital.

• Precision and Guidance: The biologic effect of PRP depends on its precise placement. The growth factors form a fibrin clot that acts as a scaffold for new tissue. If this clot is not placed directly within the tendon tear or the arthritic joint space, its effect will be lost. This is why ultrasound guidance is non-negotiable in my practice. It ensures that this valuable biologic product is delivered exactly where it is needed most.
• Addressing Biomechanical Dysfunction: Injecting PRP into a knee with poor biomechanics (e.g., due to pelvic misalignment, foot overpronation, or muscular imbalances) is like patching a tire on a car with a bent axle. The underlying mechanical stress will continue to damage the joint. As a chiropractor, my first step is to assess and correct the entire kinetic chain. Through chiropractic adjustments, soft tissue mobilization, and corrective exercises, we restore proper joint alignment and movement patterns. This reduces abnormal stress on the treated joint, creating an optimal mechanical environment for the PRP to work effectively and for the new tissue to heal and mature.
• Post-Procedure Rehabilitation: The healing initiated by PRP is a biological process that unfolds over months. It is not a quick fix. An appropriate, progressive rehabilitation program is crucial. Immediately after the procedure, there’s a period of relative rest, followed by a gradual reintroduction of movement and loading to guide the new tissue formation. This is where my team of health coaches and rehab specialists plays a key role, guiding patients through a tailored program that supports and enhances the regenerative process.

By combining the targeted biologic stimulus of high-dose, accurately placed PRP with the foundational biomechanical correction and functional rehabilitation central to chiropractic care, we create a powerful, synergistic effect. This integrative model addresses both the biological deficit and the mechanical dysfunction, leading to more durable, long-term improvements in pain, function, and quality of life for my patients.

---

References

• Fitzpatrick, J., Bulsara, M., & Zheng, M. H. (2017). The effectiveness of platelet-rich plasma in the treatment of tendinopathy: A meta-analysis of randomized controlled clinical trials. The American Journal of Sports Medicine, 45(1), 226–233.
• Vangsness, C. T., Jr, Farr, J., 2nd, Boyd, J., Dellaero, D. T., Mills, C. R., & LeRoux-Williams, M. (2021). Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. The Journal of Bone and Joint Surgery. American Volume, 96(2), 90–98.
• Filardo, G., Kon, E., Buda, R., Timoncini, A., Di Martino, A., Cenacchi, A., Fornasari, P. M., Giannini, S., & Marcacci, M. (2011). Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy, 19(4), 528–535.
• Rodeo, S. A. (2016). Biologic approaches in sports medicine: The future is now. Sports Health, 8(6), 499–500.
• Everts, P. A., Onishi, K., Jayaram, P., Lana, J. F., & Mautner, K. (2020). Platelet-rich plasma: New performance understandings and therapeutic considerations in 2020. International Journal of Molecular Sciences, 21(20), 7794.